Uncovering the Secrets to Biotech Clinical Trial Success: Insights from a New Industry Survey

Novotech, the premier Asia Pacific-based biotech CRO, teamed up with Citeline to conduct a survey among global biotech professionals, seeking to gain insights into their current and future clinical pipeline prospects, the challenges of clinical trials, and changes in study location preferences. The results of this survey provide key information to help organizations make informed decisions on their clinical research strategies.

Cost emerged as the primary worry among survey participants, with 32% citing it as their top concern. Patient recruitment followed close behind, with 29% of respondents citing it as a priority.

Biotech clinical trials are under increased scrutiny as companies seek to secure funding for the future. This report delves into the latest trends and challenges faced in this area, offering invaluable insight into the world of biotechnology. From data collection to patient recruitment, this report shines a light on the most pressing issues in the field and how to confront them.

The latest report on trends and industry professionals’ perceptions across therapeutic areas paints a fascinating picture; uncovering the current state of the industry and the various directions it is heading towards.

It provides insight into the prevailing thoughts and insights of professionals working in the sector, helping to identify potential opportunities for further growth and development. With its comprehensive analysis and data, the report serves as a valuable resource for those looking to gain a better understanding of the industry.

Cell and gene therapies (CGTs) have been identified as the most promising therapy type for investment and development in the future, with 26% of respondents agreeing. mRNA therapies (22%) and antibody therapeutics (19%) followed close behind as additional areas of potential growth.

Novotech is the go-to CRO for biotechs around the world! With offices across the US, Europe, and Asia Pacific, they offer an unparalleled suite of early to late-phase clinical trial services that are delivered expeditiously and with the highest level of quality. Their reputation for excellence has earned them the trust of many biotechs who rely on them to get the job done.

Novotech has gained international recognition for its top-tier performance in the CRO field. The company has won the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award and the Asia-Pacific Contract Research Organization Company of the Year Award. Additionally, Novotech has established 45 Leading Site Partnership agreements in the past three years, further cementing its position as a leader in the industry.

About Novotech

Novotech is the premier biotech CRO with a focus on Asia Pacific but providing global execution capabilities. With experience in over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies, Novotech is equipped to provide top-notch drug development consulting services and FDA regulatory expertise.

Boasting over 3,000 staff and 34 office locations worldwide, Novotech can facilitate your clinical trials in Asia Pacific, the US and Europe with state-of-the-art labs and phase I facilities.

Leave a Comment